// App-Quantinova.ai

POS0614 (2021) : PERFUSE: A FRENCH PROSPECTIVE/RETROSPECTIVE NONINTERVENTIONAL COHORT STUDY OF INFLIXIMAB-NAÏVE AND TRANSITIONED PATIENTS RECEIVING INFLIXIMAB BIOSIMILAR SB2; 12-MONTH ANALYSIS

Researchers

Presenter

  • B. Fautrel

Principal Investigators

  • Y. Bouhnik

  • M. Dougados

  • U. Freudensprung

  • J. Addison

Medical Centers

  • Sorbonne University, Pitié Salpêtrière Hospital,Paris,Frankrijk

  • Beaujon Hospital, APHP, Paris Diderot University, Department of Gastroenterology, Clichy, France

  • CHU Paris Centre - Hôpital Cochin, Service de Rhumatologie B, Paris, France

  • Biogen GmbH, Medical Data Science and Analytics, Biosimilars, Baar, Switzerland

  • Biogen IDEC, Clinical Research, Biosimilars, Maidenhead, United Kingdom

Locations

  • France

  • Switzerland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Musculoskeletal

  • Dermatology

Disease

  • Axial spondyloarthritis

  • Rheumatoid arthritis

  • Psoriatic arthritis

  • Spondyloarthritis

Biomarkers

  • N/A

Drug/Treatment

  • Infliximab Biosimilar

Outcome

  • N/A

Study Design

  • Non Interventional

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved